PPIDT00236
Drug Information
| Name | Histrelin |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06788 |
| Type | small molecule |
| Indication | As the product Supprelin LA (FDA), histrelin is indicated for the treatment of children with central precocious puberty (CPP).[L41700] As the product Vantas (FDA), histrelin is indicated for the palliative treatment of advanced prostate cancer.[L41715] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Implant | Subcutaneous |
|
| Implant | Subcutaneous |
50 mg/1
|
| Implant; kit | Subcutaneous |
50 mg
|